Zeo ScientifiX grants CMO 1.25M stock options
Zeo ScientifiX, Inc. reported that Chief Medical Officer George Craig Shapiro received two stock option awards.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Zeo ScientifiX, Inc. reported that Chief Medical Officer George Craig Shapiro received two stock option awards. Each grant covers 625,000 options on common stock at an exercise price of $1.67 per share, dated June 10, 2026.
One grant vests in full as of the grant date and is exercisable on a cashless basis for ten years under the 2021 Equity Incentive Plan. The other vests upon specified performance milestones and is also exercisable cashless for ten years once vested, and is described as antidilutive for future transactions issuing at least 10% of common stock on a fully diluted basis.
Insider Trade Summary
Grant/Award: 1,250,000 shares
Grant/Award
2 txns
Insider
Shapiro George Craig
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options | 625,000 | $0.00 | $0.00 |
| Grant/Award | Stock Options | 625,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options — 1,250,000 contracts (Direct)
Footnotes (2)
- F1. Represents the grant of stock options to purchase shares of the Issuer's common stock under its 2021 Equity Incentive Plan (the "2021 Plan"). The options vested in full as of the grant date, are exercisable on a "cashless basis" for a period of ten (10) years from the award date, and are subject to the other terms and conditions of the 2021 Plan.
- F2. Represents the grant of stock options to purchase shares of the Issuer's common stock under the 2021 Plan. The options vest upon the achievement of certain performance milestones, are exercisable on a "cashless basis" during the period commencing on the date they vest and ending ten (10) years from the award date, and are subject to the other terms and conditions of the 2021 Plan. The options are antidilutive for any future transaction that provides for the issuance of 10% or more of the Company's common stock outstanding on a fully diluted basis.
Key Figures
Option grant size 1: 625,000 options
Option grant size 2: 625,000 options
Total underlying shares: 1,250,000 shares
+3 more
6 metrics
Option grant size 1
625,000 options
Grant of stock options on June 10, 2026
Option grant size 2
625,000 options
Second stock option grant on June 10, 2026
Total underlying shares
1,250,000 shares
Combined underlying common shares for both grants
Exercise price
<money>$1.67</money> per share
Conversion or exercise price for each option grant
Option term
10 years
Options exercisable until June 10, 2036
Grant date
<date>June 10, 2026</date>
Transaction date for both option awards
Key Terms
2021 Equity Incentive Plan, cashless basis, performance milestones, antidilutive, +1 more
5 terms
2021 Equity Incentive Plan financial
"Represents the grant of stock options to purchase shares of the Issuer's common stock under its 2021 Equity Incentive Plan (the "2021 Plan")."
cashless basis financial
"The options vested in full as of the grant date, are exercisable on a "cashless basis" for a period of ten (10) years from the award date."
An agreement executed on a cashless basis lets a holder convert or exercise a security (like options, warrants, or conversion rights) without paying money upfront; instead the holder receives a smaller number of shares equal in value to what the cash would have purchased. Think of trading a coupon for fewer slices of a cake rather than handing over cash for the full slice. For investors, it affects how much ownership and dilution occur and avoids immediate cash outlays.
performance milestones financial
"The options vest upon the achievement of certain performance milestones, are exercisable on a "cashless basis" during the period commencing on the date they vest."
antidilutive financial
"The options are antidilutive for any future transaction that provides for the issuance of 10% or more of the Company's common stock outstanding on a fully diluted basis."
fully diluted basis financial
"10% or more of the Company's common stock outstanding on a fully diluted basis."
A fully diluted basis counts every share that could exist if all outstanding options, warrants, convertible securities and other rights were exercised or converted into common stock, showing the maximum number of shares outstanding. For investors this matters because it spreads ownership and earnings across that larger share count, like slicing a pie into every possible piece before deciding how big each investor’s slice will be, which affects per-share value and ownership percentage.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did Zeo ScientifiX (ZEOX) report for its CMO?
Zeo ScientifiX reported stock option grants to its Chief Medical Officer. On June 10, 2026, George Craig Shapiro received two option awards under the 2021 Equity Incentive Plan, representing equity-based compensation rather than open-market share purchases or sales.
What are the exercise price and term of the new Zeo ScientifiX (ZEOX) options?
Each option grant carries a $1.67 per share exercise price and a ten-year term. The options are exercisable on a cashless basis through June 10, 2036, subject to the applicable vesting terms described in Zeo ScientifiX’s 2021 Equity Incentive Plan.
How do the Zeo ScientifiX (ZEOX) option grants vest for the CMO?
One grant vests immediately and the other vests on performance milestones. The fully vested grant is exercisable as of the award date, while the performance-based grant becomes exercisable only when specified milestones are achieved, both within the 2021 Equity Incentive Plan framework.
Are the new Zeo ScientifiX (ZEOX) options exercisable on a cashless basis?
Yes, both option grants are exercisable on a cashless basis. This means Shapiro can exercise without paying cash upfront for the full share cost, using a portion of the shares’ value to cover the exercise, consistent with the plan’s terms.
What does antidilutive treatment mean for the Zeo ScientifiX (ZEOX) performance-based options?
The filing states the performance-based options are antidilutive for certain future transactions. Specifically, they are characterized as antidilutive if Zeo ScientifiX undertakes a transaction that issues at least 10% of its fully diluted common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
